Abstract:Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL We have previously reported the development of a versatile nanocarrier platform comprised of PEG-cholic acid cluster telodendrimers that can self-assemble together with hydrophobic cytotoxic anti-cancer agents to form stable nanoparticle drugs. We have successfully loaded these nanoparticles with a number of different cancer drugs. These include paclitaxel, doxorubicin, vincristine, vinblastine, actinomycin D, bortezomib, temsirolimus, sarofinib, and lapatinib. Using electron paramagnetic resonance spectroscopy, we have demonstrated that the micelles can be disrupted by LDL and VLDL causing premature drug release. Such undesirable properties can be eliminated by cross-linking the telodendrimers with disulfide bonds. The disulfide crosslinked micelles can be triggered to release drugs by endogenous glutathione inside the cancer cells or via exogenous addition of N-acetyl cysteine, a FDA approved-drug that has been used for years in the treatment of Tylenol overdose. Very recently, we created a novel crosslinking strategy by incorporating boronic acids or catechols into the telodendrimers. The final nanocarriers were crosslinked by boronate-catechol bonds resulting in stable micelles, thus avoiding premature drug release. Inside the endosomal compartment, the boronate-catechol bonds were cleaved by the acidic environment resulting in drug release. An additional very important feature of this nanocarrier is that exogenous mannitol (another FDA-approved drug for diuresis) can be administered in vivo to trigger drug release. Therapeutic studies in ovarian cancer xenograft model indicated that paclitaxel-loaded boronate-catechol crosslinked nanoparticles were much more efficacious when mannitol was given 24 hours after each dose of nanoparticle drug. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1943. doi:1538-7445.AM2012-1943

Catanionic Drug-Derivative Nano-Objects Constructed by Chlorambucil and Its Derivative for Efficient Leukaemia Therapy.

Nano-drug Delivery System for the Treatment of Acute Myelogenous Leukemia.

Novel Strategy to Fabricate PLA/Au Nanocomposites As an Efficient Drug Carrier for Human Leukemia Cells in Vitro

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Preparation of a Novel Multifunctional Cationic Liposome Drug-carrying System and its Functional Study on Lung Cancer

β-Cyclodextrin-based supramolecular nanoparticles: a pH-sensitive nanocarrier for the sustained release of the anti-tumor drug

A Novel Combinational Nanodrug Delivery System Induces Synergistic Inhibition of Lung Adenocarcinoma Cells In vitro

Combination of Small Molecule Prodrug and Nanodrug Delivery: Amphiphilic Drug-Drug Conjugate for Cancer Therapy.

Cationic liposomes as a drug-free system for efficient anticancer therapy by intracytoplasmic delivery of sodium bicarbonate

Core-Coordinated Elliptic Polymer Nanoparticles Loading Copper(II) and Chlorambucil for Cooperative Chemodynamic/Chemotherapy

On-Demand Reversible Boronate-Catechol Crosslinked Nanocarriers For Cancer Therapy

A Novel Delocalized Lipophilic Cation-Chlorambucil Conjugate Inhibits P-glycoprotein in HepG2/ADM Cells.

Synthesis, Characterization, and Cytotoxicity Evaluation of Chlorambucil-Functionalized Mesoporous Silica Nanoparticles

Micelles via self-assembly of amphiphilic beta-cyclodextrin block copolymers as drug carrier for cancer therapy

Pharmacophore Hybridisation and Nanoscale Assembly to Discover Self-Delivering Lysosomotropic New-Chemical Entities for Cancer Therapy

Copolymer Nanoparticles Composed of Sulfobetaine and Poly(ε-Caprolactone) As Novel Anticancer Drug Carriers.

Enzymatic drug release cascade from polymeric prodrug nanoassemblies enables targeted chemotherapy

Erythrocyte Membrane Camouflaged Sirna/chemodrug Nanoassemblies for Cancer Combination Therapy.

Preparation and Characterization Evaluation of Poly(L-Glutamic Acid)-g-Methoxy Poly(Ethylene Glycol)/Combretastatin A4/BLZ945 Nanoparticles for Cervical Cancer Therapy

Nucleoside Analogue-Based Supramolecular Nanodrugs Driven by Molecular Recognition for Synergistic Cancer Therapy

Drug-mediation Formation of Nanohybrids for Sequential Therapeutic Delivery in Cancer Cells.